New schizophrenia medical journal launched
Abilify users might want to take note:
Abilify users take note: A new online medical journal dedicated to advances in schizophrenia treatment being launched into production.
Elsevier, one of the world's advanced and trustworthy providers of products and services dealing with technical, scientific and medical information, has issued a press statement sharing their plans on launching a new journal Schizophrenia Research: Cognition. The journal will be available for open access, as well as being dedicated to providing and detailing all of the new advances, opinions and remedies for schizophrenia.
Schizophrenia Research: Cognition will primarily serve as a spin-off series to another Elsevier journal, Schizophrenia Research, which some consider to already be a widely recognized medical journal focused on the scientific research of the mental condition. Main overviews and content intended to be published in the new journal will include:
Dr. Philip D. Harvey, the editor-in-chief of Schizophrenia Research: Cognition, believes that the new journal will be able to provide more insight into a mental disability that still remains a mystery to most people who are fortunate not to have the disease.
"The benefits of an international, specialized open-access journal focusing on cognition in schizophrenia will include broadening access to the rapidly changing developments in the field to scientists with limited access to subscription journals," Harvey said in a statement.
If you are concerned about someone who may be displaying a combination of these symptoms, contact a doctor today and see if Abilify could be the right prescription for them. You can buy Abilify at a Canadian online pharmacy.